Skip to main content

Table 1 Demographic, laboratory, and clinical characteristics

From: Association between serum ferritin levels and clinical outcomes in maintenance hemodialysis patients: a retrospective single-center cohort study

  Total (n = 116) LF (n = 87) HF (n = 29) p value
Serum ferritin, ng/mL 50.7 (17.5–98.8) 30 (14.3–56.7) 151 (117.5–218)  
Cohort time, day 1825 (819–1825) 1825 (1008–1825) 1091 (668.5–1825)  
Age, year 65.4 ± 13.4 64.8 ± 13.5 66.9 ± 13.3 0.47
Malea 81 (70%) 59 (68%) 22 (76%) 0.49
Cause of ESRD
 Diabetic nephropathy 34 (29%) 26 (30%) 8 (28%)  
 IgA nephropathy or chronic glomerulonephritis 36 (31%) 25 (29%) 11 (38%)  
 Nephrosclerosis 12 (10%) 10 (11%) 2 (6.9%)  
 Rapid progressive glomerulonephritis 1 (0.9%) 1 (1.1%) 0 (0%)  
 Polycystic kidney disease 7 (6.0%) 6 (6.9%) 1 (3.4%)  
 Others 14 (12%) 10 (11%) 4 (14%)  
 Unknown 12 (10%) 9 (10%) 3 (10%)  
Hemoglobin, g/dL 10.8 ± 1.15 10.9 ± 1.08 10.7 ± 1.34 0.49
Serum iron, μg/dL 55.5 (38–73) 54 (35–73) 56 (45–79.5) 0.12
TIBC, μg/dL 271 (235–309) 284 (251–318) 234 (207–257) < 0.001
T-SAT, % 20.4 (14.8–27.3) 17.9 (13.3–24.6) 25.7 (19.7–34) 0.0007
Intravenous irona 27 (23%) 21 (24%) 6 (21%) 0.80
Iron dose, mg/month 42.1 ± 85.8 45.5 ± 92.1 31.7 ± 63.6 0.46
ESAa 100 (86%) 75 (86%) 25 (86%) 1.00
ESA dose, μg/week 29.9 ± 25.1 30.2 ± 24.7 29.3 ± 26.7 0.87
HD vintage, month 79 (32–136) 81 (33–138) 78 (27–124) 0.68
Kt/V (single pool) 1.40 (1.23–1.54) 1.38 (1.25–1.53) 1.43 (1.21–1.56) 0.067
Serum creatinine, mg/dL 11.9 ± 3.04 12.0 ± 3.16 11.5 ± 2.66 0.43
BUN, mg/dL 64.9 ± 16.0 64.7 ± 15.6 65.5 ± 17.3 0.83
Serum calciumb, mg/dL 9.33 ± 0.67 9.33 ± 0.67 9.35 ± 0.70 0.87
Serum phosphate, mg/dL 5.3 (4.73–5.3) 5.4 (4.9–6.3) 5.0 (4.0–5.45) 0.001
BMI, kg/m2 21.6 ± 3.50 21.8 ± 3.28 21.4 ± 4.07 0.25
Serum albumin, g/dL 3.95 (3.72–4.10) 4.0 (3.8–4.1) 3.9 (3.65–4.1) 0.22
LDL-cholesterol, mg/dL 75 (57.3–94.5) 73 (57–93) 77 (60.5–99) 0.69
CRP, mg/dl 0.07 (0–0.35) 0.05 (0–0.14) 0.30 (0.02–0.77) 0.003
History of CADa 31 (27%) 22 (25%) 9 (31%) 0.63
History of atrial fibrillationa 14 (12%) 10 (11%) 4 (14%) 0.22
History of diabetes mellitus 38 (33%) 28 (32%) 10 (34%) 0.82
History of hypertensiona 100 (86%) 73 (84%) 27 (93%) 0.35
History of dyslipidemiaa 27 (23%) 20 (23%) 7 (24%) 1.00
History of CV events 48 (41%) 34 (39%) 14 (48%) 0.38
History of gastrectomya 6 (5.2%) 3 (3.4%) 3 (10%) 0.16
History of malignancya 5 (4.3%) 4 (4.6%) 1 (3.5%) 0.34
Positive fecal occult blooda 19 (16%) 12 (16%) 7 (25%) 0.39
History of liver disordersa 14 (12%) 10 (12%) 4 (14%) 0.75
Recent hospitalizationa 8 (6.9%) 4 (4.6%) 4 (14%) 0.11
  1. Values are reported as mean ± standard deviation, median (interquartile range) or number (%) as appropriate. Comparisons were made between the two stratified populations
  2. LF low-ferritin, HF high-ferritin, ESRD end-stage renal disease, TIBC total iron binding capacity, T-SAT total iron binding capacity, ESA erythropoietin-stimulating agent, HD hemodialysis, BMI body mass index, CRP C-reactive protein, CAD coronary artery disease, CV cardiovascular
  3. aAnalyzed by Fisher’s exact test
  4. bCorrected using the following formula: Corrected calcium = serum calcium + (4 − serum albumin) (g/dL) when the albumin level is < 4 g/dL